About Xeris Biopharma Holdings, Inc.
https://www.xerispharma.comXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.
CEO
John P. Shannon
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 98
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Craig-Hallum
Buy
Jefferies
Buy
Oppenheimer
Outperform
Leerink Partners
Outperform
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:11.93M
Value:$90.41M
BLACKROCK INC.
Shares:10.33M
Value:$78.32M
VANGUARD GROUP INC
Shares:9.83M
Value:$74.5M
Summary
Showing Top 3 of 245
About Xeris Biopharma Holdings, Inc.
https://www.xerispharma.comXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $74.38M ▲ | $56.65M ▲ | $621K ▲ | 0.83% ▲ | $0 ▲ | $11.08M ▲ |
| Q2-2025 | $71.54M ▲ | $52.45M ▼ | $-1.93M ▲ | -2.7% ▲ | $-0.01 ▲ | $8.59M ▲ |
| Q1-2025 | $60.12M ▲ | $54.48M ▲ | $-9.22M ▼ | -15.34% ▼ | $-0.06 ▼ | $1.23M ▼ |
| Q4-2024 | $60.1M ▲ | $48.94M ▼ | $-5.11M ▲ | -8.51% ▲ | $-0.03 ▲ | $5.72M ▲ |
| Q3-2024 | $54.27M | $53.57M | $-15.74M | -29% | $-0.11 | $-8.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $91.6M ▲ | $370.19M ▲ | $371.05M ▲ | $-861K ▲ |
| Q2-2025 | $59.28M ▲ | $334.69M ▲ | $353.99M ▲ | $-19.3M ▲ |
| Q1-2025 | $58.44M ▼ | $315.45M ▼ | $350.58M ▼ | $-35.13M ▼ |
| Q4-2024 | $71.62M ▲ | $323.06M ▲ | $352.68M ▲ | $-29.61M ▼ |
| Q3-2024 | $69.4M | $321.1M | $349.43M | $-28.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $621K ▲ | $18.43M ▲ | $-71K ▲ | $13.85M ▲ | $0 ▼ | $18.07M ▲ |
| Q2-2025 | $-1.93M ▲ | $182K ▲ | $-279K ▼ | $942K ▲ | $845K ▲ | $10.04M ▲ |
| Q1-2025 | $-9.22M ▼ | $-10.03M ▼ | $-13K ▼ | $-3.14M ▼ | $-13.18M ▼ | $-10.04M ▼ |
| Q4-2024 | $-5.11M ▲ | $1.98M ▲ | $10.02M ▲ | $398K ▲ | $12.39M ▲ | $1.75M ▲ |
| Q3-2024 | $-15.74M | $-8.3M | $9.91M | $-83K | $1.53M | $-8.39M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 Keveyis | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Product | $100.00M ▲ | $60.00M ▼ | $70.00M ▲ | $70.00M ▲ |
 Product Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
John P. Shannon
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 98
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Craig-Hallum
Buy
Jefferies
Buy
Oppenheimer
Outperform
Leerink Partners
Outperform
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:11.93M
Value:$90.41M
BLACKROCK INC.
Shares:10.33M
Value:$78.32M
VANGUARD GROUP INC
Shares:9.83M
Value:$74.5M
Summary
Showing Top 3 of 245